Compare
Organon & Co. vs Perrigo Co PLC vs Regeneron Pharmaceuticals, Inc. vs Phibro Animal Health Corp
| Latest fiscal year | Organon & Co. OGN | Perrigo Co PLC PRGO | Regeneron Pharmaceuticals, Inc. REGN | Phibro Animal Health Corp PAHC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | $6.22B | $4.25B | $14.34B | $1.52B |
| Revenue growth (YoY) | -2.9% | -2.8% | +1.0% | +17.1% |
| Gross margin | 53.3% | 35.1% | n/a | 33.8% |
| Operating margin | n/a | -26.4% | 24.9% | 12.8% |
| Net margin | 3.0% | -33.5% | 31.4% | 6.6% |
| Net income | $187.00M | -$1.43B | $4.50B | $99.72M |
| EPS (Diluted) | $0.72 | -$10.29 | $41.48 | $2.43 |
| Operating cash flow | $700.00M | $238.50M | $4.98B | $68.95M |
| Free cash flow | $538.00M | $145.10M | $4.08B | $9.87M |
| Cash & equivalents | $574.00M | n/a | $3.12B | $61.42M |
| Total assets | $12.87B | $8.54B | $40.56B | $1.50B |
| Total liabilities | $12.12B | $5.60B | $9.30B | $1.12B |
| Shareholders' equity | $752.00M | $2.94B | $31.26B | $385.48M |
| Return on year-end equity | 24.9% | -48.6% | 14.4% | 25.9% |
| Shares outstanding | 260.32M | 137.60M | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Organon & Co. | Perrigo Co PLC | Regeneron Pharmaceuticals, Inc. | Phibro Animal Health Corp |
|---|---|---|---|---|
| Latest | $6.22B Ended 2025-12-31 | $4.25B Ended 2025-12-31 | $14.34B Ended 2025-12-31 | $1.52B Ended 2026-06-30 |
| 1 year earlier | $6.40B Ended 2024-12-31 | $4.37B Ended 2024-12-31 | $14.20B Ended 2024-12-31 | $1.30B Ended 2025-06-30 |
| 2 years earlier | $6.26B Ended 2023-12-31 | $4.66B Ended 2023-12-31 | $13.12B Ended 2023-12-31 | $1.02B Ended 2024-06-30 |
| 3 years earlier | $6.17B Ended 2022-12-31 | $4.45B Ended 2022-12-31 | $12.17B Ended 2022-12-31 | $977.89M Ended 2023-06-30 |
| 4 years earlier | $6.30B Ended 2021-12-31 | $4.14B Ended 2021-12-31 | $16.07B Ended 2021-12-31 | $942.26M Ended 2022-06-30 |